Article

Glutathione pathway genes and lung cancer risk in young and old populations

Division of Epidemiology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Carcinogenesis (Impact Factor: 5.27). 11/2004; 25(10):1935-44. DOI: 10.1093/carcin/bgh203
Source: PubMed

ABSTRACT Multiple enzymes with overlapping functions and shared substrates in the glutathione (GSH) metabolic pathway have been associated with host susceptibility to tobacco smoke carcinogens and in lung cancer etiology. However, few studies have investigated the differing and interacting roles of GSH pathway enzymes with tobacco smoke exposure on lung cancer risk in young (<50 years of age) and old (>80 years of age) populations. Between 1997 and 2001, 237 primary lung cancer patients (170 young, 67 old) and 234 controls (165 young, 69 old) were enrolled at the Mayo Clinic. Using PCR amplification of genomic DNA, polymorphic markers for gammaGCS, GPX1, GSTP1 (I105V and A114V), GSTM1 and GSTT1 were genotyped. Recursive partitioning and logistic regression models were used to build binary classification trees and to estimate odds ratios (OR) and 95% confidence intervals for each splitting factor. For the young age group, cigarette smoking had the greatest association with lung cancer (OR = 3.3). For never smokers, the dividing factors of recursive partitioning were GSTT1 (OR = 1.7), GPX1 (OR = 0.6) and GSTM1 (OR = 4.3). For the old age group, smoking had the greatest association with lung cancer (OR = 3.6). For smokers, the dividing factors were GPX1 (OR = 3.3) and GSTP1 (I105V) (OR = 4.1). Results from logistic regression analyses supported the results from RPART models. GSH pathway genes are associated with lung cancer development in young and old populations through differing interactions with cigarette smoking and family history. Carefully evaluating multiple levels of gene-environment and gene-gene interactions is critical in assessing lung cancer risk.

Download full-text

Full-text

Available from: Mariza Andrade, Feb 24, 2014
0 Followers
 · 
81 Views
  • Source
    • "Four studies have looked at the association between the Pro198Leu polymorphism and the risk of lung cancer [24] [32] [33] [46]. Compared to Pro homozygotes, two studies – in Finland and Korea – found a significantly increased risk of lung cancer in Leu hetero/homozygotes [24] [32], while a small US study found a significantly-increased risk in neversmoker Leu hetero-/homozygotes (only 13 cases), though a significantly-decreased risk was found in elderly smokers [46]. However, in the fourth study, carried out in Denmark, Leu/Leu homozygosity was associated with decreased risk [33]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Knowledge of the plasma selenium levels associated with optimised concentration or activity of specific selenoproteins can provide considerable insights from epidemiological data on the possible involvement of those selenoproteins in health, most notably with respect to cancer. For cohort studies, if selenoproteins such as glutathione peroxidase and selenoprotein P are relevant to cancer, one might only expect to see an effect on risk when the concentrations in the cohort range from below, to above, the level needed to optimise the activity or concentration of these enzymes. Similarly, trials would only show a beneficial effect of supplementation if selenium status were raised from below, to above, the optimal concentration for the selenoproteins likely to be implicated in cancer risk, as occurred in the NPC trial but not in SELECT. The most powerful evidence for the involvement of selenoproteins in human health comes from epidemiological studies that have related single nucleotide polymorphisms in selenoproteins to disease risk. The totality of the evidence currently implicates GPx1, GPx4, SEPS1, Sep15, SEPP1 and TXNRD1 in conditions such as cardiovascular disease, pre-eclampsia and cancer. Future studies therefore need to determine not only selenium status, but genotype, both in selenoproteins and related pathways, when investigating the relationship of selenium with disease risk.
    Biochimica et Biophysica Acta 04/2009; 1790(11):1533-40. DOI:10.1016/j.bbagen.2009.03.014 · 4.66 Impact Factor
  • Source
    • "The importance of accounting for gene-gene interactions in the search for susceptibility genes for complex diseases has been widely suggested to explain difficulties in replicating significant findings. Recent human and animal studies of complex diseases have identified susceptibility genes that marginally contribute to a common trait, to a minor extent only or not at all, but that interact significantly in combined analyses (Kuida and Beier 2000; Naber et al. 2000; Williams et al. 2000; Hsueh et al. 2001; Kim et al. 2001; Tripodis et al. 2001; Ukkola et al. 2001; Barlassina et al. 2002; De Miglio et al. 2004; Yanchina et al. 2004; Yang et al. 2004; Aston et al. 2005; Dong et al. 2005; Roldan et al. 2005). Several investigators have found alleles that have opposite effects depending on the genetic background (Balmain and Harris 2000; Staessen et al. 2001), which further raises the likelihood of overlooking epistatic susceptibility genes in single-gene analyses (Culverhouse 2002). "
    [Show abstract] [Hide abstract]
    ABSTRACT: An efficient testing strategy called the "focused interaction testing framework" (FITF) was developed to identify susceptibility genes involved in epistatic interactions for case-control studies of candidate genes. In the FITF approach, likelihood-ratio tests are performed in stages that increase in the order of interaction considered. Joint tests of main effects and interactions are performed conditional on significant lower-order effects. A reduction in the number of tests performed is achieved by prescreening gene combinations with a goodness-of-fit chi2 statistic that depends on association among candidate genes in the pooled case-control group. Multiple testing is accounted for by controlling false-discovery rates. Simulation analysis demonstrated that the FITF approach is more powerful than marginal tests of candidate genes. FITF also outperformed multifactor dimensionality reduction when interactions involved additive, dominant, or recessive genes. In an application to asthma case-control data from the Children's Health Study, FITF identified a significant multilocus effect between the nicotinamide adenine dinucleotide (phosphate) reduced:quinone oxidoreductase gene (NQO1), myeloperoxidase gene (MPO), and catalase gene (CAT) (unadjusted P = .00026), three genes that are involved in the oxidative stress pathway. In an independent data set consisting primarily of African American and Asian American children, these three genes also showed a significant association with asthma status (P = .0008).
    The American Journal of Human Genetics 02/2006; 78(1):15-27. DOI:10.1086/498850 · 10.99 Impact Factor
  • 01/1970: pages 75-111;
Show more